Diagnostic and therapeutic use of proton pump inhibitors in non-cardiac chest pain: A metaanalysis

American Journal of Gastroenterology

Volumn 100, Issue 6, 2005, Pages 1226-1232

  Cremonini, Filippo ^b   Wise, James ^b   Moayyedi, Paul ^b   Talley, Nicholas J ^a  

^a MAYO CLINIC   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

LANSOPRAZOLE; OMEPRAZOLE; PLACEBO; PROTON PUMP INHIBITOR; RABEPRAZOLE;

ARTICLE; CLINICAL TRIAL; COCHRANE LIBRARY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DRUG EFFECT; DRUG EFFICACY; EMBASE; ENDOSCOPY; GASTROESOPHAGEAL REFLUX; HUMAN; MEDLINE; META ANALYSIS; NON CARDIAC CHEST PAIN; PH MEASUREMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; SENSITIVITY ANALYSIS; SYSTEMATIC REVIEW; THORAX PAIN;

ANTI-ULCER AGENTS; CHEST PAIN; DIAGNOSIS, DIFFERENTIAL; GASTROESOPHAGEAL REFLUX; HUMANS; ODDS RATIO; PROTON PUMPS; RANDOMIZED CONTROLLED TRIALS; RETROSPECTIVE STUDIES; ROC CURVE; TIME FACTORS; TREATMENT OUTCOME;

EID: 21344438166     PISSN: 00029270     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1572-0241.2005.41657.x     Document Type: Article

References (24)

1. Eslick GD. Noncardiac chest pain: Epidemiology, natural history, health care seeking, and quality of life. Gastroenterol Clin N Am 2004;33:1-23.
2. Eslick GD, Coulshed DS, Talley NJ. Review article: The burden of illness of non-cardiac chest pain. Aliment Pharmacol Ther 2002;16:1217-23.
3. Pass R, Naliboff B, Higa L, et al. Differential effect of long-term esophageal acid exposure on mechanosensitivity and chemosensitivity in humans. Gastroenterology 1998;115:1363-73.
4. Beedassy A, Katz PO, Gruber A, et al. Prior sensitization of esophageal mucosa by acid reflux predisposes to reflux-induced chest pain. J Clin Gastroenterol 2000;31:121-4.
5. Kahrilas PJ. Esophageal motility disorders: Current concepts of pathogenesis and treatment. Can J Gastroenterol 2000;14:221-31.
6. Richter JE, Barish CF, Castell DO. Abnormal sensory perception in patients with esophageal chest pain. Gastroenterology 1986;91:845-52.
7. Wise CM, Semble EL, Dalton CB. Musculoskeletal chest wall syndromes in patients with noncardiac chest pain: A study of 100 patients. Arch Phys Med Rehabil 1992;73:147-9.
8. Olden K. The psychological aspects of noncardiac chest pain. Gastroenterol Clin N Am 2004;33:61-7.
9. Fass R, Fennerty MB, Ofman JJ, et al. The clinical and economic value of a short course of omeprazole in patients with noncardiac chest pain. Gastroenterology 1998;115:42-9.
10. Ofman JJ, Gralnek IM, Udani J, et al. The cost-effectiveness of the omeprazole test in patients with noncardiac chest pain. Am J Med 1999;107:219-27.
11. Moher D, Cook DJ, Eastwood S, et al. Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement. Quality of reporting of metaanalyses. Lancet 1999;354:1896-900.
12. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986;7:177-88.
13. Egger M, Davey Smith G, Schneider M, et al. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997;315:629-34.
14. Decks JJ. Systematic reviews in health care: Systematic reviews of evaluations of diagnostic and screening tests. BMJ 2001;323:157-62.
15. Achem SR, Kolts BE, MacMath T, et al. Effects of omeprazole versus placebo in treatment of noncardiac chest pain and gastroesophageal reflux. Dig Dis Sci 1997;42:2138-45.
16. Bautista J, Fullerton H, Briseno M, et al. The effect of an empirical trial of high-dose lansoprazole on symptom response of patients with non-cardiac chest pain-A randomized, double-blind, placebo-controlled, crossover trial. Aliment Pharmacol Ther 2004;19:1123-30.
17. Fass R, Fullerton H, Hayden CW, et al. Patients with noncardiac chest pain receiving an empirical trial of high dose rabeprazole demonstrate early symptom response-A double-blind, placebo-controlled trial. Gastroenterology 2002;122:A580-81.
18. Pandak WM, Arezo S, Everett S, et al. Short course of omeprazole: A better first diagnostic approach to noncardiac chest pain than endoscopy, manometry, or 24-hour esophageal pH monitoring. J Clin Gastroenterol 2002;35:307-14.
19. Squillace SJ, Young MF, Sanowski RA. Single dose omeprazole as a test for noncardiac chest pain. Gastroenterology 1993;104:A197.
20. Xia HH, Lai KC, Lam SK, et al. Symptomatic response to lansoprazole predicts abnormal acid reflux in endoscopy-negative patients with non-cardiac chest pain. Aliment Pharmacol Ther 2003;17:369-77.
21. Chambers J, Cooke R, Anggiansah A, Owen W. Effect of omeprazole in patients with chest pain and normal coronary anatomy: Initial experience. Int J Cardiol 1998;65:51-5.
22. Dekel R, Martinez-Hawthorne SD, Guillen RJ, et al. Evaluation of symptom index in identifying gastroesophageal reflux disease-related noncardiac chest pain. J Clin Gastroenterol 2004;38:24-9.
23. Numans ME, Lau J, de Wit NJ, et al. Short-term treatment with proton-pump inhibitors as a test for gastroesophageal reflux disease: A meta-analysis of diagnostic test characteristics. Ann Intern Med 2004;140:518-27.
24. Veldhuyzen van Zanten SJ, Talley NJ, Bytzer P, et al. Design of treatment trials for functional gastrointestinal disorders. Gut 1999;45 (Suppl 2):II69-77.